Press release
Top Players and Competitive Dynamics in the Biosimilar Hormones Market
Biosimilar Hormones Market
Projected Market Size and Growth Trajectory of the Biosimilar Hormones Market
The biosimilar hormones market is anticipated to experience rapid growth, reaching a valuation of $18.12 billion by 2030. This corresponds to an impressive compound annual growth rate (CAGR) of 23.9%. Several elements contribute to this surge, including the expiration of patents for major biologic hormones, stronger regulatory backing for biosimilar products, and a rising need for more affordable endocrine therapies. Additionally, the expansion of online pharmacies as distribution channels and increased investments in biosimilar research and development are fueling market growth. Prominent trends shaping this period include heightened acceptance of biosimilar hormones as cost-effective alternatives, escalating demand for insulin and growth hormone biosimilars, broader physician adoption of biosimilar treatments, expanded uses in chronic and lifestyle diseases, and streamlined regulatory processes facilitating faster approvals.
Download a free sample of the biosimilar hormones market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3432&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR
Leading Companies Influencing the Biosimilar Hormones Market Landscape
The biosimilar hormones sector is dominated by a range of well-established pharmaceutical players. Key companies include Teva Pharmaceutical Industries Ltd., Gedeon Richter Plc., Intas Pharmaceuticals Ltd., Biocon Limited, Mylan, Sanofi, Sandoz Group AG, LG Life Sciences, Ferring Pharmaceuticals, GC Pharma, Pfizer Inc., Dr. Reddy's Laboratories, Amgen Inc., Eli Lilly and Company, Celltrion Inc., Samsungbioepis Co. Ltd, Merck & Co., Biogen Inc., Boehringer Ingelheim, Alvotech, Cipla Limited, Lupin Ltd., Stada Arzneimittel AG, Torrent Pharmaceuticals, Zydus Cadila, Accord Healthcare, Hetero Drugs, and Wockhardt. These organizations play a crucial role in driving product innovation, market penetration, and competitive dynamics.
Key Trends Driving Innovation and Growth in the Biosimilar Hormones Industry
Innovation is a central theme in the biosimilar hormones market, with companies developing new products to enhance treatment options and profitability. A notable example is the introduction of Sogroya (somapacitan-beco) injection, a human growth hormone analog designed to treat growth hormone deficiency.
View the full biosimilar hormones market report:
https://www.thebusinessresearchcompany.com/report/biosimilar-hormone-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Jul_PR
In a significant development, Novo Nordisk, a pharmaceutical company based in Denmark, secured FDA approval in April 2023 for an expanded indication of Sogroya to treat children aged 2.5 years and older experiencing growth failure due to insufficient endogenous growth hormone secretion. Sogroya is distinguished as the only once-weekly growth hormone therapy approved for use in both pediatric and adult patients. This approval was supported by the phase 3 REAL4 clinical trial results, which demonstrated the drug's effectiveness in managing growth hormone deficiency among children.
Detailed Segmentation of the Biosimilar Hormones Market
The biosimilar hormones market is organized into various segments to provide a comprehensive understanding of its scope:
1) By Type:
- Teriparatide Biosimilars
- Follitropin Alfa Biosimilars
- Insulin Biosimilars
- Somatropin Biosimilars
- Other Types
2) By Application:
- Research & Biotechnology
- Therapeutics
- Other Applications
3) By Distribution Channel:
- Hospital and Retail Pharmacy
- Online Pharmacy
- Specialty Clinics
Further segmentation includes:
- Teriparatide Biosimilars used primarily for osteoporosis treatment and bone health maintenance.
- Follitropin Alfa Biosimilars applied in infertility treatment and assisted reproductive technologies (ART).
- Insulin Biosimilars for managing Type 1 and Type 2 diabetes.
- Somatropin Biosimilars targeting growth hormone deficiency and pediatric growth disorders.
- Other types comprising thyroid hormones and corticosteroids.
This detailed breakdown offers insights into where demand is concentrated and highlights growth opportunities across different therapeutic areas and distribution methods.
Our latest 2026 market reports provide expanded strategic and visual intelligence with market attractiveness scoring and analysis, total addressable market (TAM) analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, together with updated graphics and tables.
Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Learn More About The Business Research Company
With over 30,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Top Players and Competitive Dynamics in the Biosimilar Hormones Market here
News-ID: 4592563 • Views: …
More Releases from The Business Research Company
Trypsin-EDTA Solution For Cell Dissociation Market Research Reveals Path To $2.0 …
The trypsin-EDTA solution for cell dissociation market is poised for remarkable expansion as advances in cell therapy and biomanufacturing continue to accelerate. With increasing demands for efficient and reliable cell processing methods, this sector is on track to experience dynamic growth over the next several years. The following overview explores the market's anticipated size, leading companies, emerging trends, and key segmentations shaping its future.
Projected Market Size and Growth Path for…
Triple Negative Breast Cancer Market Demonstrates Long-Term Growth Potential At …
An in-depth look into the triple negative breast cancer market reveals promising growth and significant advancements in treatment options. As research intensifies and new therapies emerge, this sector is poised for notable expansion and increased innovation in the coming years.
Projected Market Growth of the Triple Negative Breast Cancer Market by 2030
The market for triple negative breast cancer is anticipated to experience substantial growth, reaching a valuation of $1.48…
Treatment-Resistant Depression Market Outlook Signals Expansion To $2.59 Billion …
The treatment-resistant depression market is on track for significant expansion as new therapies and technologies emerge to address persistent challenges in managing this complex condition. With ongoing advancements in personalized medicine and digital health, this sector is expected to evolve rapidly in the coming years. Here's an in-depth look at the market size, key players, influential trends, and detailed segmentation shaping the industry's outlook.
Forecast of the Treatment-Resistant Depression Market Size…
Traumatic Brain Injuries Assessment Market Report 2026 Market Outlook Supported …
The assessment of traumatic brain injuries (TBI) is a rapidly evolving field, driven by technological advancements and a growing need for precise and timely diagnosis. As healthcare providers seek more effective tools to evaluate brain trauma, the market for TBI assessment is poised for notable expansion. Below is an in-depth look at how this market is expected to develop, the leading players involved, and the trends shaping its future.
Traumatic Brain…
More Releases for Biosimilar
Interchangeable Biosimilar Humira Market Share Driven by Biologic Therapy Adopti …
Interchangeable Biosimilar Humira Market
The global market for Interchangeable Biosimilar Humira was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period
View sample report
https://reports.valuates.com/request/sample/QYRE-Auto-33I15005/Global_Interchangeable_Biosimilar_Humira_Market_Research_Report_2023
The Interchangeable Biosimilar Humira Market is experiencing significant market growth as healthcare providers and patients increasingly adopt biosimilar therapies for autoimmune and inflammatory conditions. Market trends indicate rising…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Key Trend Reshaping the Biosimilar Monoclonal Antibodies Market in 2025: Advance …
What Are the Projections for the Size and Growth Rate of the Biosimilar Monoclonal Antibodies Market?
In recent times, the biosimilar monoclonal antibodies sector has experienced a swift expansion. The market size, which stands at $8.04 billion in 2024, is projected to climb to $9.25 billion in 2025, marking a compound annual growth rate (CAGR) of 15.1%. Factors such as expired patents, an increased understanding of biosimilars, governmental strategies, heightened financial…
Biosimilar Market Treating More for Less: The Booming Infliximab Biosimilar Mark …
Infliximab Biosimilar Market worth $ XX Million by 2030 - Exclusive Report by InsightAce Analytic
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Infliximab Biosimilar Market- by Application (Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis and Others), End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Other Direct Distribution Channels), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."
Get…
Biosimilar Monoclonal Antibodies Market
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Biosimilar Monoclonal Antibodies Market by Product (infliximab, trastuzumab, rituximab, adalimumab, bevacizumab, cetuximab, ranibizumab, denosumab, eculizumab, and other pipeline products), Indication (oncology, inflammatory & autoimmune disorders, chronic diseases, blood disorders, and other indications), Clinical Trial/Pipeline Analysis, Future Trends, Industry Competition Analysis, Revenue and Forecast To 2031."
The Biosimilar Monoclonal Antibodies Market Size is valued at 5.02…
Infliximab Biosimilar Insight, 2022 | DelveInsight
DelveInsight's, "Infliximab Biosimilar Insight, 2022" report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Infliximab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Interested to know more about the functioning of…
